New Equity Funding announced by Huntingdon Life Sciences and Harlan Laboratories

Huntingdon Life Sciences (HLS) and Harlan Laboratories have announced that institutional investors have dedicated up to $125 million in minority-equity financing that can fund future growth initiatives.

The new company will have the name Envigo.

"We recently announced our rebranding of the company to Envigo as we complete the integration of HLS and Harlan to broaden the support we provide to life science research," CEO Brian Cass said. "This equity investment of up to $125 million validates the success of that integration and further strengthens the Company's balance sheet to pursue additional organic and strategic investments. We look forward to leveraging the resources of the investor group as we continue to grow Envigo and enhance our market leading position."

When Envigo launches in a few months, it will have 3,800 employees and revenue of approximately $500 million. It will be the largest provider of research services for crop protection and chemical industries, the second-largest supplier of research models and services, and the third-largest provider of preclinical research services to the pharmaceutical industry.